Research

CRB Monitor is closely following the latest developments in cannabis rescheduling. Question: Were cannabis investors given the straight scoop about...

It has been more than 19 months since President Joe Biden injected life (or at least, hope) into the cannabis...

The pace of cannabis business licensing in North America slowed in the first quarter of 2024, with active licenses declining...

Cannabis Equity Returns The Nasdaq CRB Monitor Global Cannabis Index (HERBAL) had a positive 24.2% return for the 3rd quarter...

This month, we turn our attention to the Sunshine State, where the Florida Supreme Court has issued its decision that...

It has been about a year since we have written about the sometimes dysfunctional relationship amongst Tier 1 Pure Play,...

February reminded us once again that “we can’t have nice things” in the cannabis market, at least not for very...

January 2024 provided further evidence that the cannabis industry not only has a pulse but might actually pull itself together...

The CRB Monitor Securities Research team covers all aspects of the publicly-traded cannabis ecosystem, including the regulatory environment, operational expansion/M&A...

With the hysteria over The announcement that the US Department of Health and Human Services recommended rescheduling cannabis to Schedule...